An observational study in Vaginal Prolapse, sponsored by Rambam Health Care Campus. Terminated at 1 site in Israel. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-09-16.
Sponsored by Rambam Health Care Campus · Observational
Female pregnant patients in their 2nd trimester will be evaluated for vaginal elasticity using vaginal tactile imaging in addition to elasticity evaluation during the 3rd trimester and 6 weeks postpartum.
Female pregnant patients in their 2nd trimester will be evaluated for vaginal elasticity using vaginal tactile imaging. Vaginal elasticity will also be evaluated during the 3rd trimester and 6 weeks postpartum.
Patients will be recruited and sign a consent form. Assessment of vaginal elasticity via vaginal tactile imaging will be performed at 3 different points:
111 studies on the registry are indexed under Uterine Prolapse; 20 are open to participants now.
This study's enrollment of 12 is below the median of 132 across 28 observational studies indexed under Uterine Prolapse.
Browse Uterine Prolapse studies →Rambam Health Care Campus is the lead sponsor of 456 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Pregnant patients in their 2nd trimester with no regard to previous obstetric history.
Exclusion Criteria:
Pregnant patients in their 2nd trimester.
Diagnostic Test: Vaginal tactile imager
Vaginal elasticity evaluation by vaginal tactile imaging analysis.
Vaginal elasticity
Vaginal elasticity evaluation by vaginal tactile imaging analysis
Time frame: From the beginning of the 2nd trimester of pregnancy up to 6 weeks postpartum.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is terminated, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rambam Health Care Campus